Does Highmark Blue Cross Blue Shield Cover Weight Loss Treatment in Delaware? A 2026 Guide

Last updated: July 23, 2026

If you have Highmark Blue Cross Blue Shield in Delaware and you’re exploring weight loss treatment options, understanding how your plan may cover medications, behavioral programs, and provider visits is an important first step. Highmark BCBS DE commercial plans typically provide some level of weight loss benefit, though coverage details vary by specific plan design, your employer’s benefit elections, and whether prior authorization requirements are met.

This guide covers how Highmark BCBS DE, using Express Scripts (ESI) as its pharmacy benefit manager, may handle weight loss medications in 2026, what Delaware law does and does not require, and how to navigate prior authorization and appeals if coverage is denied.

Ready to explore weight loss treatment? Klarity Health connects you with licensed providers who can evaluate your options and discuss what may fit your health goals. See if you may qualify →

Key Facts at a Glance

Insurer: Highmark Blue Cross Blue Shield Delaware
Pharmacy Benefit Manager (PBM): Express Scripts (ESI)
State parity law: Del. Code Ann. tit. 18, § 3343. Applies to mental health and substance use disorder benefits only; does not govern weight loss coverage
Governing framework: ACA Essential Health Benefits (EHB) standards + individual plan design
Delaware EPCS: Phentermine and Qsymia (Schedule IV) require electronic prescribing; GLP-1s, Contrave, and orlistat are non-scheduled. EPCS entirely inapplicable
Medicare GLP-1 Bridge: Not applicable to Highmark BCBS DE commercial plans (Humana Medicare Advantage only)
Highmark Member Services: 1-800-241-5704
ESI Pharmacy: 1-800-792-9558
DE Insurance Commissioner: 1-302-674-7300

Does Delaware State Law Require Weight Loss Coverage?

Delaware’s primary insurance parity statute. Del. Code Ann. tit. 18, § 3343. Aligns with the federal Mental Health Parity and Addiction Equity Act (MHPAEA). This law requires that mental health and substance use disorder benefits be provided at parity with medical and surgical benefits. However, § 3343 does not govern weight loss coverage. Weight management is not classified as a mental health or substance use disorder benefit under Delaware or federal parity law.

Weight loss medication coverage for Highmark BCBS DE commercial plans is instead governed by the Affordable Care Act’s Essential Health Benefits framework and each plan’s specific benefit design. Delaware does not have a state statute requiring commercial insurers to cover FDA-approved weight loss medications, which means coverage is largely determined at the plan level.

If you have an employer-sponsored self-funded ERISA plan through Highmark, your employer sets the benefit design. Self-funded plans are not subject to Delaware state insurance mandates. Fully insured Delaware plans must comply with Delaware Department of Insurance regulations, but no state mandate currently requires weight loss drug coverage.

How Highmark BCBS DE (ESI) May Cover Weight Loss Medications in 2026

Highmark BCBS DE uses Express Scripts (ESI) as its pharmacy benefit manager. ESI’s commercial formulary typically includes FDA-approved weight loss medications, though coverage, tier placement, and prior authorization requirements vary by plan. Below is a general overview of how ESI commonly handles major weight loss drugs. Always verify your specific plan’s formulary at highmarkbcbs.com or by calling ESI at 1-800-792-9558.

Key ESI distinction: Unlike CVS/Caremark (Aetna’s PBM), which removed Zepbound from formulary and is reinstating it October 1, 2026, ESI did not remove Zepbound. Highmark BCBS DE members with an ESI formulary plan may have continued access to Zepbound at Tier 3. 4 throughout 2025. 2026, subject to prior authorization.

Delaware EPCS Requirements for Weight Loss Medications

Delaware requires electronic prescribing for controlled substances (EPCS) under Delaware regulations (see Del. Code Ann. tit. 16, § 4798A and Board of Medical Licensure and Discipline regulations). For weight loss medications, the EPCS picture is straightforward:

Most FDA-approved weight loss medications prescribed via telehealth. Including GLP-1 injections, Contrave, and orlistat. Are non-scheduled and therefore not subject to Delaware EPCS requirements. Phentermine and Qsymia (Schedule IV) do require EPCS when prescribed in Delaware, and providers must use a certified EPCS-compliant electronic prescribing system.

Prior Authorization for Weight Loss Medications Under ESI

Prior authorization (PA) is common for GLP-1 weight loss medications on ESI commercial plans. Typical PA criteria include:

• BMI threshold: BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documented diet and exercise: Evidence of participation in a structured diet and exercise program, or documentation that behavioral interventions have been attempted
• Prescriber specialty: Some ESI plans require prescribing by or in consultation with an appropriate specialist or primary care provider with weight management documentation
• Contraindication check: No contraindications to the specific medication (e.g., personal or family history of medullary thyroid carcinoma for GLP-1s)
• Prior therapy: Some plans require a trial of behavioral intervention or a lower-tier weight loss agent before approving a GLP-1

PA approvals are typically issued for 6. 12 months and require renewal with documentation of ongoing treatment response (usually ≥5% body weight reduction).

How to Start the Prior Authorization Process

1. Confirm your plan includes weight loss medication coverage by calling Highmark at 1-800-241-5704 or reviewing your Summary of Benefits and Coverage
2. Ask your provider to submit a PA request through ESI’s electronic PA portal or by calling ESI at 1-800-792-9558
3. Gather supporting documentation: BMI measurement, diagnosis codes (obesity E66.x), comorbidity records, and any prior weight management program records
4. ESI typically reviews PA requests within 72 hours; urgent requests may be reviewed within 24 hours
5. If approved, confirm the specialty pharmacy that will fill the medication (GLP-1 injectables are often dispensed by specialty pharmacies)

What If Your Plan Does Not Cover Weight Loss Medications?

Not all Highmark BCBS DE plans cover FDA-approved weight loss medications. Some employer-sponsored plans explicitly exclude weight loss drugs from the pharmacy benefit. If your plan excludes coverage:

• Check your plan documents: Review your Summary of Benefits and Coverage or Evidence of Coverage for language about “weight loss” or “obesity” exclusions
• Manufacturer savings programs: Novo Nordisk (Wegovy), Eli Lilly (Zepbound), and other manufacturers offer savings cards and patient assistance programs for those who don’t qualify for insurance coverage
• Medical benefit vs. pharmacy benefit: Surgical interventions and some medically supervised programs may be covered under the medical benefit even when drugs are excluded from the pharmacy benefit
• Appeal a denial: If your plan covers weight loss treatment but denied a specific medication, you have the right to appeal

How to Appeal a Highmark BCBS DE Weight Loss Medication Denial

If Highmark or ESI denies coverage for a weight loss medication, you have several options:

1. Internal appeal: Submit a formal appeal to Highmark within the timeframe specified in your denial letter (typically 180 days). Include your provider’s clinical notes, BMI documentation, prior treatment history, and medical necessity statement. Call Highmark at 1-800-241-5704 to request the appeals process
2. External review: If the internal appeal is denied, you may request an independent external review. Delaware law requires insurers to offer external review for adverse benefit determinations. Contact the Delaware Department of Insurance at 1-302-674-7300 to understand your external review rights
3. Peer-to-peer review: Your prescribing provider can request a peer-to-peer (P2P) review with Highmark’s or ESI’s medical director before or during the appeals process. P2P reviews are often effective for GLP-1 approvals when clinical documentation is strong
4. ERISA appeal (employer plans): For employer-sponsored self-funded plans, contact the U.S. Department of Labor EBSA at 1-866-444-3272. ERISA provides appeal rights for self-funded plan members that differ from state insurance regulations
5. DE DOI complaint: If you believe Highmark is improperly denying a covered benefit, file a complaint with the Delaware Department of Insurance Consumer Services Division at 1-302-674-7300

Understanding the Parity Limitation for Weight Loss

Delaware’s insurance parity law (Del. Code Ann. tit. 18, § 3343) and the federal MHPAEA apply specifically to mental health and substance use disorder benefits. Weight loss treatment does not fall under these parity protections. This means insurers can apply coverage limitations, higher cost-sharing, or outright exclusions for weight loss medications without triggering parity obligations.

Some advocates argue that obesity should be classified as a medical condition warranting parity protection, and federal legislation has been proposed to this effect. As of mid-2026, however, weight loss coverage remains outside the scope of parity law in Delaware and at the federal level.

How Klarity Health Can Help

Klarity Health has a network of 2,000+ licensed providers who can evaluate your weight management goals and discuss FDA-approved treatment options. Including GLP-1 medications and other evidence-based approaches. Klarity providers operate across Delaware and can work with your Highmark BCBS DE insurance as an in-network or out-of-network provider depending on your plan.

Your provider can also assist with prior authorization documentation, ensuring that your clinical record includes BMI measurements, comorbidity documentation, and prior treatment history in the format ESI typically requires for GLP-1 approvals.

Check if you may qualify for weight loss treatment. Klarity Health’s licensed providers can help you explore your options and navigate insurance requirements. Get started →

Frequently Asked Questions

Does Highmark BCBS DE cover Wegovy?
Wegovy may be covered under some Highmark BCBS DE commercial plans that include FDA-approved weight loss medications in the pharmacy benefit. Coverage typically requires prior authorization with BMI ≥30 or ≥27 with a comorbidity. Verify your specific plan by calling ESI at 1-800-792-9558 or Highmark at 1-800-241-5704.

Does Highmark BCBS DE cover Zepbound?
Zepbound (tirzepatide for weight loss) was not removed from ESI’s formulary, unlike CVS/Caremark which removed it and plans to reinstate it on October 1, 2026. Highmark BCBS DE members on an ESI formulary plan may have access to Zepbound at Tier 3. 4, subject to prior authorization. Confirm with ESI at 1-800-792-9558.

Does Delaware law require Highmark to cover weight loss medications?
No. Delaware’s parity law (§ 3343) covers mental health and substance use disorder benefits only. There is no Delaware state statute requiring commercial insurers to cover FDA-approved weight loss medications. Coverage depends on your specific plan design and benefit elections.

Do I need EPCS for a weight loss prescription in Delaware?
It depends on the medication. Phentermine and Qsymia are Schedule IV controlled substances and require electronic prescribing (EPCS) in Delaware. GLP-1 medications (Wegovy, Zepbound, Saxenda), Contrave, and orlistat are non-scheduled and do not require EPCS.

Is the Medicare GLP-1 Bridge available for Highmark BCBS DE members?
No. The Medicare GLP-1 Bridge ($50/month for Wegovy, Zepbound, or Foundayo via CMS) is available only to eligible Medicare Advantage (MAPD) members. Currently through Humana MAPD plans. Highmark BCBS DE commercial plan members are not eligible for the Medicare GLP-1 Bridge program.

What if my employer’s Highmark plan excludes weight loss medications entirely?
Some self-funded employer plans through Highmark exclude weight loss drugs from the pharmacy benefit. In this case, manufacturer savings programs (Novo Nordisk, Eli Lilly) may reduce out-of-pocket costs. You may also explore medically supervised programs that could be covered under the medical benefit. Contact Highmark at 1-800-241-5704 or your HR department to review your plan’s specific coverage.

Key Contacts

• Highmark BCBS DE Member Services: 1-800-241-5704
• Express Scripts (ESI) Pharmacy: 1-800-792-9558
• Delaware Department of Insurance: 1-302-674-7300
• U.S. Department of Labor EBSA (ERISA plans): 1-866-444-3272
• CMS (Medicare inquiries): 1-800-633-4227

Disclaimer: Coverage information in this guide is general in nature and reflects commonly available plan structures as of 2026. Actual coverage for weight loss treatment under your Highmark BCBS DE plan depends on your specific plan documents, benefit elections, and prior authorization determinations. Coverage details may change. Always verify your benefits directly with Highmark at 1-800-241-5704 or ESI at 1-800-792-9558 before beginning treatment. This content is for informational purposes only and does not constitute insurance, legal, or medical advice. Klarity Health providers can help you understand your options; insurance verification is your responsibility as the plan member.